Lori Handy, MD, provides guidance in these areas including presentation before rash onset, when patients should be considered for the inpatient setting, and what treatment looks like.
|Videos|July 6, 2020
Gaining Insights into Islatravir and Doravirine
Author(s)John Parkinson
Carey Hwang, MD, PhD, executive director and product development lead, Global Clinical Development of Infectious Disease at Merck spoke with Contagion® regarding the therapies and went further into depth about the studies.
Advertisement
As the virtual
For example, Merck released new data today from its Phase 2b trial regarding islatravir, the company’s investigational oral nucleoside reverse transcriptase translocation inhibitor in combination with doravirine in adults with
Results included the tolerability and safety profile of islatravir in combination with doravirine (100 mg) through week 48 across three dose levels including 0.25, 0.75, and 2.25 mg.
Carey Hwang, MD, PhD, executive director and product development lead, Global Clinical Development of Infectious Disease at Merck spoke with Contagion® regarding the therapies and went further into depth about the studies.
Hwang also spoke about unmet needs including the current HIV population and the unique challenges behind this aging patient group.
In addition, he spoke of medical research continuing despite the
Advertisement
Related to this article
Jason Pogue, PharmD, BCPS, BCIDP, contextualizes preliminary data looking at this trial and other extended-spectrum beta-lactamase (ESBL) studies, which reopens the debate around carbapenem-sparing treatment options.
With a significant increase in rabies exposures this year, Rodney Rohde, PhD, talks about seeking medical attention after animal interactions as well as clinical treatment when people have been bit or scratched.
In the first episode of our new series looking at the food safety network, Lynette Johnston, PhD, offers insights into how the federal government surveillance infrastructure operates and how epidemiologists serve as food detectives in determining bacterial pathogens and potential foodborne outbreaks.
Food expert Lynette Johnston, PhD, provides some context around the ongoing outbreak, discusses prevention, and compares 2026 food recalls with previous years.
The Peggy Lillis Foundation will host its 17th Annual Changing the Odds Gala this month in New York City, and it will include a casino, fellowship amongst the C diff community, and an award ceremony honoring a physician-scientist, philanthropist, a researcher, and a patient advocate for their contributions to C difficile awareness, treatment, and prevention.
Resistance-guided testing targeting a single gene mutation could let clinicians safely reintroduce ciprofloxacin for the majority of gonorrhea cases still susceptible to it, sparing ceftriaxone as resistance climbs worldwide. Lao-Tzu Allan-Blitz, MD, MPH, offers insights into his work in this area.
The latest CDC numbers show a 6.2% increase of measles cases from week-to-week. Last week there was a 5.4% increase in cases showing a continuing steady increase dictated by ongoing outbreaks across the US.
Advertisement
Advertisement
Trending on Contagion Live
1
New IDSA/ESCMID S aureus Bacteremia Consensus Statements: a Risk Stratification Framework
2
Measles Update: October 2, 2026
3
FAQ: Rising Rabies Exposure Calls PEP Decisions Back in Focus
4
Clinical Considerations for Measles: Presentation, Treatment, and Hospitalization
5